Crescent Biopharma Inc. has announced the approval of stock options for five non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The grant covers a total of 117,339 ordinary shares, with an exercise price of $10.15 per share, matching the closing price on January 29, 2026. The options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary of each employee’s start date and the remainder vesting monthly thereafter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646229-en) on January 30, 2026, and is solely responsible for the information contained therein.
Comments